Why I’d buy this small-cap over Genus plc despite today’s positive results

This smaller company has better growth prospects than Genus plc (LON: GNS).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Leading animal genetics company Genus (LSE: GNS) has released a positive trading update today. In spite of mixed market conditions, Genus made progress towards its strategic objectives and is performing in line with expectations for the full year. Despite this, healthcare peer Eco Animal Health (LSE: EAH) has brighter long-term prospects.

Genus’s customers endured a rather mixed period from July to November. Strong pig production volumes in some markets such as the US caused substantially lower pig prices in those regions. However, in other regions such as Europe and China, pig prices either improved or remained strong. This supported robust demand for Genus’s PIC genetics as well as volume growth.

Meanwhile, dairy prices began to improve on a global basis. However, they remain at levels where a significant proportion of dairy farmers are unprofitable. Beef prices in the US declined throughout the period, which meant that Genus’s customers adopted a more cautious approach to demand. These challenging conditions led to lower semen volumes for Genus ABS, while IVB continued to grow embryo volumes.

Looking ahead, Genus is forecast to increase its earnings by 6% in the current year. While this rate of growth is roughly in line with that of the wider market, Genus trades on a high-growth valuation that its forecasts don’t reflect. For example, Genus has a price-to-earnings (P/E) ratio of 29.8 and when this is combined with its rating, it equates to a price-to-earnings growth (PEG) ratio of 5. This indicates that Genus is overvalued at the present time.

Small is beautiful?

That’s a key reason why fellow healthcare company Eco Animal Health has huge appeal in comparison. Unlike Genus, Eco Animal Health is expected to record strong growth in both the current and next year. Its earnings are expected to rise by 34% this year and by a further 17% next year. When combined with its P/E ratio of 51.2, this equates to a much more appealing PEG ratio of 2.

Certainly, Eco Animal Health is a smaller business and lacks the size, scale and financial firepower of Genus. However, it has an excellent record of delivering above average growth over a long period. For example, in the last five years Eco Animal Health’s earnings have risen by 130% and it’s not unreasonable to expect them to record a similarly strong growth rate over the next five years.

While Genus is a high quality company that has excellent long-term growth prospects, its valuation is too high to merit purchase at the present time. That’s especially the case since an upgrade to its guidance may not be on the cards as the pig and dairy markets offer rather mixed outlooks. Therefore, for long-term investors buying Eco Animal Health is the logical solution, while also waiting for an improved share price for Genus before buying a slice of it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of ECO Animal Health Group. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

The National Grid share price just plunged another 10%. Time to buy?

The National Grid share price is one of the FTSE 100's most stable, and nothing much happens to it? Well,…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Up 15% in 3 months, but I still won’t touch Vodafone shares with a bargepole

Harvey Jones has been shunning Vodafone shares for years. The FTSE 100 stock is finally showing signs of life, but…

Read more »

Growth Shares

This UK stock could be like buying Nvidia in 2021

Jon Smith thinks he's missed the boat with Nvidia shares, but flags up a UK stock that has some very…

Read more »

Businesswoman calculating finances in an office
Investing Articles

The FTSE 100’s Intertek delivers a bullish update — can the share price soar?

I’d describe Intertek as a quality business with a decent dividend income, but will the share price shoot the lights…

Read more »

Market Movers

Up another 10% yesterday, how high can the Nvidia share price go?

Jon Smith talks through the latest results but flags up why further gains could be harder to come by for…

Read more »

Investing For Beginners

Down 43% in a year, I think this value stock is primed for a comeback

Jon Smith flags up why a FTSE 250 share has fallen so much in the recent past, but explains why…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Nvidia stock is stupidly expensive. Or is it?

Nvidia stock's up over 2,000% in the past five years. Christopher Ruane explains why it could be wildly overvalued --…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

The FTSE 100 stock I’ve been buying this week

Stephen Wright thinks the FTSE 100 slipping back this week has offered an opportunity in one of the highest-quality UK…

Read more »